Pro-urokinase for Extended-Window Posterior Circulation Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 586 participants.
Also called NCT07617870
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 586 participants
- Registry
-
NCT07617870
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07617870. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pro-urokinase for Extended-Window Posterior Circulation Stroke
- Acronym
- PROMISE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- rhPro-UK
- Intervention (Drug)
- placebo
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Placebo
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
Record details
- Record id
cardio:ct-nct07617870- Content hash
766d75041a5d964fd83ee9f827954b7fc51dcebd2b8afa807ad6b3dd84f48011